

PAPER • OPEN ACCESS


# Detecting drug-target binding in cells using fluorescence-activated cell sorting coupled with mass spectrometry analysis

To cite this article: Kris Wilson *et al* 2018 *Methods Appl. Fluoresc.* **6** 015002

View the [article online](#) for updates and enhancements.

## Related content

- [Hyaluronic acid-fabricated nanogold delivery of the inhibitor of apoptosis protein-2 siRNAs inhibits benzo\[a\]pyrene-induced oncogenic properties of lung cancer A549 cells](#)  
Chung-Ming Lin, Wei-Chien Kao, Chun-An Yeh *et al.*
- [RNAi-based therapeutic nanostrategy: IL-8 gene silencing in pancreatic cancer cells using gold nanorods delivery vehicles](#)  
Nishtha Panwar, Chengbin Yang, Feng Yin *et al.*
- [Exploiting fluorescence for multiplex immunoassays on protein microarrays](#)  
Melinda Herbáth, Krisztián Papp, Andrea Balogh *et al.*



The advertisement banner features a red background with white text and images. On the left is the Edinburgh Instruments logo, a stylized circular pattern of dots, with the text 'EDINBURGH INSTRUMENTS' and 'EXPERTS in FLUORESCENCE SPECTROSCOPY' below it. In the center, there are two main product images: the FLS1000 Photoluminescence Spectrometer and the FS5 Photon Counting Spectrofluorometer. To the right of the FS5 image is a list of capabilities: TIME-RESOLVED FLUORESCENCE, STEADY STATE FLUORESCENCE, PHOSPHORESCENCE LIFETIME, and TRANSIENT ABSORPTION. A small white waveform graphic is at the bottom left of the banner.

**EDINBURGH INSTRUMENTS**

EXPERTS in FLUORESCENCE SPECTROSCOPY

**FLS1000**  
PHOTOLUMINESCENCE SPECTROMETER

**FS5 PHOTON**  
COUNTING SPECTROFLUOROMETER

TIME-RESOLVED FLUORESCENCE  
STEADY STATE FLUORESCENCE  
PHOSPHORESCENCE LIFETIME  
TRANSIENT ABSORPTION

## Methods and Applications in Fluorescence



### PAPER

# Detecting drug-target binding in cells using fluorescence-activated cell sorting coupled with mass spectrometry analysis

#### OPEN ACCESS

RECEIVED  
4 April 2017

REVISED  
26 August 2017

ACCEPTED FOR PUBLICATION  
13 September 2017

PUBLISHED  
18 December 2017

Original content from this work may be used under the terms of the [Creative Commons Attribution 3.0 licence](#).

Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.



Kris Wilson<sup>1,5</sup>, Scott P Webster<sup>1</sup>, John P Iredale<sup>2,6</sup>, Xiaozhong Zheng<sup>2</sup>, Natalie Z Homer<sup>3</sup>, Nhan T Pham<sup>4</sup>, Manfred Auer<sup>4,7,8</sup> and Damian J Mole<sup>2,7,8</sup>

<sup>1</sup> Drug Discovery Core, University/BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom

<sup>2</sup> MRC Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom

<sup>3</sup> Mass Spectrometry Core, University/BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom

<sup>4</sup> School of Biological Sciences and Medical School, University of Edinburgh, C.H. Waddington Building, King's Buildings, Max Born Crescent, Edinburgh EH9 3BF, United Kingdom

<sup>5</sup> Current address: GLAZgo Discovery Centre, Sir Graeme Davies Building, 120 University Place, University of Glasgow G12 8TA, United Kingdom.

<sup>6</sup> Current address: Office of the Pro-Vice Chancellor (Health), University of Bristol BS8 1TH, United Kingdom.

<sup>7</sup> Denotes joint senior authors and joint corresponding authors.

<sup>8</sup> Authors to whom any correspondence should be addressed.

**E-mail:** [damian.mole@ed.ac.uk](mailto:damian.mole@ed.ac.uk) and [manfred.auer@ed.ac.uk](mailto:manfred.auer@ed.ac.uk)

**Keywords:** drug discovery, flow cytometry, intracellular target engagement, kynurenine monooxygenase, fluorescence-activated cell sorting, FACS

### Abstract

The assessment of drug-target engagement for determining the efficacy of a compound inside cells remains challenging, particularly for difficult target proteins. Existing techniques are more suited to soluble protein targets. Difficult target proteins include those with challenging *in vitro* solubility, stability or purification properties that preclude target isolation. Here, we report a novel technique that measures intracellular compound-target complex formation, as well as cellular permeability, specificity and cytotoxicity—the toxicity-affinity-permeability-selectivity (TAPS) technique. The TAPS assay is exemplified here using human kynurenine 3-monooxygenase (KMO), a challenging intracellular membrane protein target of significant current interest. TAPS confirmed target binding of known KMO inhibitors inside cells. We conclude that the TAPS assay can be used to facilitate intracellular hit validation on most, if not all intracellular drug targets.

### Introduction

The efficacy of a drug relies upon interaction with a relevant therapeutic target protein at the physiological site of activity. Direct detection of this interaction *in vitro* remains a challenge, particularly if isolated protein cannot be obtained or if a suitable assay method cannot be designed. The measurement of binding of a hit, lead or drug to its intended target is particularly challenging in cells. Therefore, detection of target engagement is one of the major challenges in hit validation from phenotypic assays [1–3]. Several methods have been reported for detection of drug-target engagement. A selection of creative techniques which utilise functionalised drugs or probes with

fluorescence polarised imaging have recently been described [4–7]. Others use chemoproteomic methods to profile the spectrum of proteins interacting with chemical probes [8]. Such techniques require specialised/adapted instruments and/or capacity for production of fluorescently labelled probes. The current standard for demonstrating intracellular target engagement is the cellular thermal shift assay (CETSA), which detects ligand-induced thermal stabilisation of target proteins [9–11]. However, the authors state that the method is ‘not likely to work for highly inhomogeneous proteins’. In general, challenging drug targets which are not readily expressed in a soluble form, which are unstable in solution or which behave differently in the absence of key co-factors or

protein binding partners pose difficulties. We developed the TAPS method to provide a solution for this gap in target engagement measurement and to extend the toolbox of approaches for soluble protein targets. TAPS combines fluorescence activated cell sorting (FACS) with liquid chromatography mass spectrometry (LC-MS/MS) analysis to detect binding of drugs to their target inside cells in a concentration-dependent manner producing results which resemble an apparent binding curve of a small molecule to a target in any cellular context. Additionally, TAPS selects, in a single assay method, compounds with sufficient cellular permeability, and excludes, via necessary controls, compounds which lack specificity or demonstrate high cytotoxicity. This method is generally applicable for any intracellular target which can be expressed as a fluorescent fusion protein and its applicability to challenging membrane proteins is demonstrated here.

The TAPS technique involves transient expression of the gene of interest as a fluorescent protein conjugate in an appropriate cell type to generate a range of target concentrations. Thus, fluorescently tagged target proteins are assayed in a cellular environment in the presence of endogenous co-factors and protein-protein interactors in a physiologically relevant tissue. The protein is produced within 24 h and the transfected cells are incubated with single or pooled compounds. Cells are subjected to FACS analysis and sorted according to fluorescence intensity exhibited by the fluorescent fusion protein. Lysis of the sorted populations is followed by LC-MS/MS analysis, allowing comparison of compounds bound in target-free non-transfected cells and those bound in the fluorescently intense cells expressing varying levels of the target protein. Negative cells resulting from transient expression in these experiments act as an important integral control allowing the specificity of drug binding to be determined. In cases where it is not possible to transiently express a target protein of interest, stably transfected cell lines can be utilised in parallel with the native non-transfected cell line to perform the TAPS assay.

The TAPS assay was developed using the mitochondrial membrane associated enzyme kynurenine 3-monooxygenase (KMO). This enzyme is emerging as an increasingly important target for drug development since it has recently been implicated as a therapeutic target for Huntington's disease [12] and multiple organ failure caused by severe acute pancreatitis [13]. However, human KMO is difficult to produce and isolate in a recombinant form since it is membrane-associated and requires the presence of a lipid and proteinaceous environment to maintain activity. The hydrophobic membrane-targeting domain at the C-terminus of this NADPH-dependant flavoprotein hydroxylase is believed to be responsible for its low aqueous solubility, poor stability, and tendency to aggregate with other membrane proteins

when expressed recombinantly [14–16]. Therefore, the importance of assaying drug-KMO engagement directly in mammalian cells in the presence of co-factors and intracellular binding proteins required for enzyme functionality was paramount. Development and successful application of the TAPS method for assaying compounds against KMO inside cells provides a strong indication that this technique is applicable for targeting other challenging proteins.

## Materials and methods

### Cloning

The E2-Crimson-human KMO gene (Cys452 variant) was synthesised by GenScript in vector pUC57. The DNA sequence for E2-crimson was sourced from Clontech. The gene for the fluorescent-KMO fusion was ligated into vector pCDNA3.1 (Invitrogen) using restriction sites NheI (N-terminus) and NotI (C-terminus).

### Transient expression of fluorescent target protein

HEK293 cells were passaged in poly-*D*-Lysine treated plates and incubated overnight in OPTI-MEM medium (Lonza) at 37 °C, 5% CO<sub>2</sub>. The cells were transiently transfected the following day with pcDNA3.1-E2-Crimson-huKMO DNA using Lipofectamine 2000 (Invitrogen) in OPTI-MEM medium by standard transfection protocol. Transfection medium was removed from the cells 6 h post-transfection and replaced with DMEM containing 10% FBS, 1% L-glutamine and 1% penicillin-streptomycin (Life Technologies). The transfected cells were maintained at 37 °C, 5% CO<sub>2</sub> for 24–48 h post-transfection before the TAPS assay was performed. Transfection of the cells and the subsequent assay were performed in a variety of plate formats (6-, 12-, 24- and 48-well) during development of the assay, compound screening was performed in 6-well plate format.

### TAPS assay

#### Step 1: Compound incubation

Compounds were diluted to a concentration of 20 μM (DMSO <1%) in tissue culture medium (DMEM with 10% FBS, 1% L-Glutamine, 1% penicillin-streptomycin), then incubated with the transfected cells for four hours at 37 °C, 5% CO<sub>2</sub>. 20 μM compound concentration was selected as an appropriate concentration for assay development and screening. Following incubation, the cells were detached from the plate by gentle pipetting and centrifuged for 5 min at 1000 rpm. Culture medium was removed by pipetting and the cell pellet re-suspended in FACS buffer (PBS + 2% FBS) to wash off unbound compound. The cells were centrifuged, as above, and the wash buffer removed. The cells were then re-suspended in FACS buffer and transferred to 5 ml FACS tubes. The tubes were wrapped in foil and placed on ice until sorting.

### Step 2: FACS sorting

Cells were sorted using a BD FACS Aria II system fitted with a 100  $\mu\text{m}$  nozzle. Data was acquired and processed using BD FACSDiva Software version 6.1.3. Cell fluorescence was detected using the APC channel, using the 640 nm laser at 40 mWatt for E2-Crimson excitation. The filter used was 670/14 nm detecting fluorescence emission of E2-Crimson in the 663–677 nm range. Cells were sorted and collected into four cell populations defined by fluorescence intensity, forward (FSC) and side scatter (SSC) gating was used to exclude dead cells and only live cells were collected. Cells were collected in 5 ml FACS tubes containing 1 ml of DMEM with 10% FBS, 1% *L*-Glutamine and 1% penicillin-streptomycin. Each population of cells was centrifuged at 1000 rpm for 5 min. Medium was removed and the cell pellet resuspended in 20 mM HEPES, pH 7.0. The suspension was briefly sonicated to lyse the cells before centrifugation, as before, to pellet cell debris. The lysate (supernatant) was transferred to LC-MS vials and stored at  $-20\text{ }^{\circ}\text{C}$  prior to MS analysis.

### Step 3: Mass spectrometry detection of compounds in cell lysates

#### Instrumentation

This method was previously described by us [17]. The chromatographic system used was a TurboFlow<sup>TM</sup> TLX Aria-1 system (Thermo Fisher Scientific, Hemel Hempstead, UK), consisting of two Allegros pumps defined as the loading and eluting pumps, two valve-switching modules and a CTC liquid autosampler. The detection was carried out using a TSQ Quantum Discovery triple quadrupole mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK).

#### Chromatography and mass spectrometry parameter optimisation

Samples were subject to online-extraction using a TurboFlow<sup>TM</sup> TLX Aria-1 system operated in focus mode. 10  $\mu\text{l}$  injection of the cell lysate was loaded directly onto a C18PXL (50  $\times$  0.5 mm, ThermoFisher Scientific, Hemel Hempstead, UK) TurboFlow<sup>TM</sup> column at a high flow rate, causing the proteinaceous material to flow to waste. A series of valve switches led to the elution of the extracted sample from the TurboFlow<sup>TM</sup> column directly onto the analytical column. Solvent A was water with 0.1% formic acid, Solvent B was methanol with 0.1% formic acid and Solvent C was 45:45:10 acetonitrile:isopropanol:acetone.

Following TurboFlow<sup>TM</sup> extraction, the analytes were subsequently separated on a reverse phase T3 Atlantis (2.1  $\times$  150 mm, 3  $\mu\text{m}$ , Waters, Manchester, UK) analytical column, protected by a Kinetex Krud-Katcher<sup>®</sup> (Phenomenex, Macclesfield, UK). The analytical column was maintained at 5  $^{\circ}\text{C}$  using a column chiller.

The online TurboFlow system Aria-1 was directly connected to a Quantum Discovery triple quadrupole mass spectrometer, operated in electrospray ion mode with polarity switching for positive and negative ion monitoring. The source temperature was 300  $^{\circ}\text{C}$ , the spray voltage 3 kV and the skimmer offset was 12 V. Argon, the collision gas in Q2, had a pressure of 1.5 mTorr. Automated tune settings were used to achieve the maximum ion signal for each analyte for initial validation experiments, optimising on tube lens voltage, parent to product transitions and collision energy for each transition. A quantifier and qualifier ion was determined for each analyte. By monitoring for quantifier and qualifier ions this adds additional specificity to the assay. Acceptable quantifier: qualifier peak area ratios in biological samples were considered to be those that fell within 20% of the average ratio seen in standards. By applying tune settings, a peak area could be generated for each compound. For pooled compound screening, tune settings were not used. Samples were subject to a full MS scan with the molecular weight detection range set at 250–465 (Daltons). Peaks detected in this initial scan were then identified by molecular weight and checked versus their mass-charge ratio.

A scan width of  $m/z$  0.5, scan time of 0.1 s and unit resolution on Q1 and Q3 were applied. Data was collected as centroid data to minimise the file sizes. Data were acquired and processed using Aria 1.3, Xcalibur 1.4 and LC Quan 2.0 SP1 software packages.





#### Compounds

Three known KMO inhibitors from the patent and scientific literature [18, 19] and a non-binding compound from the University of Edinburgh Drug Discovery Core compound library were used for assay development and validation (figure 1). 100 compounds selected from the University of Edinburgh Drug Discovery Core compound library were pooled with compounds 1, 2 and 3 (figure 1) and assayed simultaneously as a mixture to demonstrate multi-compound screening. The screening library comprised of a diverse set of compounds including compounds inactive at KMO and the three well-characterised cell permeable KMO inhibitors. Inactive compounds included those known to be cell permeable at other targets. The compound set contained diverse chemistry with a range of molecular weights (169–445 Da) and lipophilicities (LogP 0.94–6.1).

#### KMO activity assay

All compounds assayed in the compound 'pool' were evaluated for activity against human KMO in a KMO activity assay. The source of KMO protein for this assay was lysate generated using the following stable cell line.

HEK293 (Flp-In-293 which express lacZ-Zeocin, Life Technologies) cells were stably co-transfected

Compound	Structure	CAS No.	IC <sub>50</sub> Against Rat KMO (nM)	IC <sub>50</sub> (nM) HuKMO
1		168154-95-8	200	482 ± 69
2		199666-03-0	37	469 ± 33
3		199602-05-6	39	1274 ± 47
4		1187466-45-0	Non-Binder	Inactive

**Figure 1.** The structures and activities of compounds used to validate the cellular TAPS method. CAS numbers and literature reported activities for rat KMO enzyme are shown for Cpd 1–4 alongside the IC<sub>50</sub> values generated by us previously in a KMO activity assay against human enzyme [17].

with 9  $\mu\text{g}$  of pcDNA5/FRT/V5/HisTOPO DNA and 18  $\mu\text{g}$  of pog44 plasmid. Pog44 expresses Flp recombinase protein, co-transfection of pog44 with the gene of interest allows targeted integration into the mammalian cell genome within a transcriptionally active region. Transfection was carried out using Lipofectamine 2000 (Life Technologies) in OPTI-MEM medium (Lonza). Cells were selected for two weeks using Hygromycin B (Sigma Aldrich) at 100  $\mu\text{g ml}^{-1}$  to select for the hygromycin resistance gene contained within the pcDNA5 vector before positive colonies were isolated and cultured.

HEK-huKMO cell lysate was analysed for KMO enzymatic activity by measuring the amount of KYN converted to 3HK detected using liquid chromatography-mass spectrometry (LC-MS/MS) following incubation with the compounds screened in the TAPS assay using a method we described previously [17]. Compounds were tested in a one compound per well format in this assay. Briefly, lysate containing 200  $\mu\text{g}$  total protein was incubated with 4 mM  $\text{MgCl}_2$ , 1 mM NADPH and 200  $\mu\text{M}$  L-Kynurenine in 20 mM HEPES, pH 7.0 for two hours at 37 °C with gentle shaking at 250 rpm in a total assay volume of 100  $\mu\text{l}$ . Samples were added to 500  $\mu\text{l}$  acetonitrile (containing

25  $\mu\text{g ml}^{-1}$  of internal standard, d5-TRP) to terminate activity, followed by centrifugation at 4000 rpm for 20 min to pellet the precipitate. The supernatant fraction was dried under nitrogen, and the residue re-suspended in 30:70 methanol:water with 0.1% formic acid ready for LC-MS/MS analysis.

LC-MS analysis was carried out using the TSQ Quantum Discovery triple quadrupole mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK) using a pentafluorophenyl (PFP) fused pore column (Waters), at 40 °C. The injection volume was 10  $\mu\text{l}$  and the flow rate was 500  $\mu\text{l min}^{-1}$ . The method had a run time of 4 min and d5 Tryptophan was used as an internal standard. Qualifier and quantifier peaks were identified for 3HK and for d5 Tryptophan. Data was acquired and processed using Xcalibur 1.4 and LC Quan 2.0 SP1 software packages.

#### Cell staining

HEK293 cells were transiently transfected and sorted by FACS as described above. A sample of cells from each sorted population were plated in transparent 96 well plates (Whatman) and incubated overnight at 37 °C, 5%  $\text{CO}_2$ . Medium was aspirated from the cells the following day and the cells gently rinsed with PBS<sup>+</sup>



(PBS containing 1 mM  $\text{Ca}^{2+}$  and 0.5 mM  $\text{MgCl}_2$ ). Wheat germ agglutinin-AlexaFluor488 conjugate was used at a concentration of  $5 \mu\text{g ml}^{-1}$  to stain the cell membranes by incubation for 10 min at  $37^\circ\text{C}$ . The stain was removed and the cells rinsed twice with  $\text{PBS}^+$ . The cells were then fixed by 10 min incubation in 3.7% formaldehyde diluted in  $\text{PBS}^+$ . After removal of the fixative, cells were thoroughly rinsed three times by 5 min incubation in  $\text{PBS}^+$ . To permeabilise the cells, 0.1% Triton-X 100 in PBS was added for 5 min at room temperature. Cells were washed a further three times before incubation with 300 nM DAPI in PBS for 5 min at room temperature in the dark to allow nuclear staining. Cells were washed a final three times in PBS. The cells were imaged using the Opera<sup>TM</sup> High Content screening system. E2-Crimson-huKMO fluorescence was detected using the 640 nm laser (2000  $\mu\text{W}$ , 280 ms), nuclear (DAPI) staining was detected using the UV light source (365 nm excitation, emission filter 450/50, 40 ms) and the 488 nm laser (1250  $\mu\text{W}$ , 40 ms) was used to detect the cell membrane stain (wheat germ agglutinin-Alexa488 conjugate).

## Results

### Selection and validation of KMO inhibitors

Three known inhibitors of KMO, with nanomolar to micromolar affinity [18, 19], and one structurally related, negative control compound (figure 1) were selected for development and validation of the TAPS assay. The activity of these inhibitors was verified by us previously against human KMO [17] in the enzyme activity assay described in the methods section and the  $\text{IC}_{50}$  values generated were in a similar range to literature values reported against rat KMO enzyme for compounds 1–3 (figure 1). Compound 4 was confirmed to be inactive in the activity assay (figure 1).

### Cellular E2-crimson fluorescence correlates with KMO activity

KMO was detectable in the cellular matrix as a far red fluorescent conjugate by fusion with E2-Crimson [20]. A broad range of cellular fluorescence intensities resulting from transient expression of fluorescent KMO were detected and sorted by FACS to generate the cell populations for MS analysis. Confocal imaging of cells from the sorted populations was used as a parallel method to confirm KMO expression (figures 2(a), (b)). Sorted cell populations, when lysed and assayed for KMO enzymatic activity, showed good correlation between increased fluorescence intensity and KMO enzyme activity (figure 2(c)). Therefore, cellular E2-Crimson fluorescence reliably indicated KMO expression and functionality.

### Intracellular target-binding of KMO inhibitors is detected in the TAPS assay


LC-MS/MS detection of the KMO inhibitors (Cpds 1–3) in cell population lysates in the TAPS assay correlated strongly and in a concentration dependent way with levels of target expression, indicating specific inhibitor affinity for KMO (figure 3(a)). MS detection of inactive compound 4 demonstrated very low and approximately equal signal in all cell population lysates, indicating little or no specific affinity for KMO (figure 3(a)). Furthermore, LC-MS/MS compound detection in fluorescent KMO-positive samples reflected the half maximal inhibitory concentrations generated in the KMO activity assay (figure 3(b)). This suggests that the compounds are demonstrating intracellular affinity for KMO and not its E2-Crimson fusion partner. These results show that the TAPS assay protocol can be utilised to identify cell permeable compounds with specific binding affinity for KMO.

### Intracellular target-binding compounds can be detected from a pooled compound mixture

To test the multiplexing potential of the technique, 103 compounds at a final concentration of 20  $\mu\text{M}$  each, including validation compounds 1, 2 and 3, were assayed simultaneously in one cellular incubation mix. Compounds 1, 2 and 3 were the only compounds to be detected solely in the high fluorescence-KMO positive sample indicating that the TAPS assay can be applied for testing medium sized compound collections (figure 3(b)). This screen also identified compounds with equal detection across all samples indicating non-specific binding or high cellular permeability. These results were verified by compound testing in the KMO activity assay (figure 3(b)). Binding specificity was shown to correlate with inhibitory activity in the activity assay confirming reliable identification of hit and false positive compounds in the TAPS assay.

## Discussion


Monitoring of drug-target engagement inside cells represents a challenge in the early drug discovery process. Molina *et al* [9] described the CETSA which addresses intracellular drug-target engagement but also confirmed that the method is unsuitable for inhomogenous proteins or those which do not aggregate upon unfolding of the ligand-binding domain. Thus there is a need for methods which are applicable to difficult target proteins and for simultaneously testing large sets of test compounds for the evaluation of drug-to-protein binding inside cells. The TAPS assay compares compound detection in cells which demonstrate variable expression of target protein. Utilising known inhibitors of our selected target enzyme, it was shown that the specific affinity of these compounds for the target could be indicated by comparing compound accumulation in cells with



over-expressed levels of target protein compared to non-specific accumulation in normal cells. Compounds with equivalent accumulation in overexpressing cells compared to untransfected cells are identified as non-specific binders and excluded. Because only cell permeable target specific binders are comparatively enriched in overexpressing cells, relative compound binding affinity and cellular permeability can be revealed simultaneously by MS analysis. Key control experiments include testing the compound(s) of interest in incubation with variably and transiently transfected cells, fluorescent protein only transfected cells, and, if needed, relevant target mutants and related proteins. Where transient expression of a target protein cannot be achieved, a similar analysis can be provided utilising stably transfected cells versus non-transfected cells. The caveat for either iteration of the assay is the requirement for expression

of fluorescently-tagged target protein. Also, the micro-plate format applied to assay a particular target, i.e. the throughput which can be achieved, depends upon the level of protein expression since the quantity of bound compound detected correlates with the quantity of protein present. Endogenous expression of the target protein should be considered when selecting cells for TAPS analysis.

We selected KMO, a challenging but increasingly important target enzyme, for development of this assay. Protein targets, like KMO, which require complexation with cellular interactome proteins or chemical co-factors pose difficulties for *in vitro* biochemical preparation and testing. To overcome these specific challenges we omitted enzyme purification steps and assayed target enzymes directly in mammalian cells in the presence of co-factors and intracellular binding proteins required for enzyme functionality. HEK293



cells were selected for analysis of KMO in the TAPS assay. Whilst KMO is expressed by kidney cells, HEK293 cells do not exhibit detectable KMO activity [20]. Thus, HEK293 cells provide a physiologically relevant matrix for the assay but the outcome of the analysis was unlikely to be impacted by endogenous KMO. More generically for all targets, if endogenous expression of the target is abundant in the cell type used, we acknowledge that this could have the potential to confound the results. In those circumstances, it would be possible to select another cell-type, this may not be necessary given that the important measure of compound-target binding is the relative enrichment of compound in cells expressing fluorescent target compared to non-fluorescent. Therefore, as long as the unknown compounds are tested in excess, as we have done, binding should be apparent. Successful application of this method to membrane proteins

indicates suitability for assay of other challenging targets such as full length protein–protein interaction partners or proteins which are only stable in the presence of nucleic acids or lipids.

KMO was detectable in the cellular matrix following fusion with E2-Crimson [21]. FACS and confocal imaging experiments confirmed that cellular E2-Crimson fluorescence reliably indicated KMO expression and functionality. Transient transfection of cells inevitably resulted in variable expression of fluorescent target protein allowing extraction of a negative control sample and a KMO-positive sample from the same cellular drug incubation. This step in the assay facilitates discrimination between compounds demonstrating non-specific cellular component binding in all cells from compounds exhibiting specific binding affinity in cells expressing higher concentrations of target protein. Detection of the known KMO



inhibitors in the TAPS assay correlated in a concentration dependent manner with levels of target expression, indicating specific affinity for KMO. The known inactive compound demonstrated an invariable signal regardless of target expression, indicating little or no specific affinity for KMO but also no unspecific or promiscuous binding cellular proteins. Detection of these compounds in the TAPS assay reflected the half maximal inhibitory concentrations generated using the KMO activity assay. Differences in the apparent intracellular binding curves, particularly of the two compounds with similar  $IC_{50}$ s are most likely connected to cellular uptake, unspecific binding events or compound-specific ionisation during MS readout.

As a next step in the TAPS assay development we tested the multiplexing potential of the technique. 103 compounds were assayed simultaneously in one cellular incubation mix. Detection of the three known KMO inhibitors in the high fluorescence-KMO positive sample suggested suitability of TAPS for testing medium sized compound collections. The screen discriminated compounds showing non-specific binding or high cellular permeability from known KMO-binding compounds with results successfully validated in the KMO activity assay. By comparing the output from each method we were able to confirm reliable identification of hit and false positive compounds in the TAPS assay.

The TAPS method is a multi-parameter tool that delivers on several aspects of compound characterisation. Whilst target binding and cellular permeability is assessed for compounds detected by MS readout, compounds demonstrating cellular cytotoxicity are excluded at the FACS step of the assay. FACS analysis was programmed to incorporate only live healthy cells, by utilising forward scatter and side scatter gating to eliminate dead cells, meaning that compounds with undesirable cytotoxicity potential are eradicated from the screen. Should further activity data be required for compounds tested by TAPS, lysates resulting from FACS analysis can be directly applied to secondary activity assays, such as the enzyme activity assay demonstrated here. In an alternative assay configuration, a cellular permeabilisation step, like automated optoinjection using LEAP, can successfully be incorporated in the TAPS assay to enable utilisation of the TAPS method for compounds which are not required to permeate the cells (data not shown).

We currently consider that the TAPS assay could be quickly and smoothly integrated into biochemical and biophysical affinity selection, enzymatic and phenotypic screening workflows to prove that any hit compounds engage with the target under investigation. In addition, the TAPS assay might also offer significant value in its potential for medium throughput, multiplexed screening of experimentally challenging protein targets, like intracellular membrane proteins, which are otherwise hindered by a lack of a suitable screening technique. Development and

application of the TAPS assay for screening compounds against KMO inside cells indicates that this technique is suitable for targeting other challenging proteins. Besides screening intracellular membrane proteins we also consider TAPS to be the method of choice for intracellular affinity selection assays for larger scale multi-protein complexes containing targetable protein-protein interactions or not easily purifiable targets, such as full length kinases. The excellent quantification possibility of both, protein concentration via fluorescent protein intensity, as well as compound concentration via MS will also allow addressing so far unresolved questions about inhibitor to protein stoichiometry in disease versus healthy cells. An other further iteration of this method will utilise primary tissue cultures. This will enable optimal, physiologically relevant host cell selection tailored to specific target proteins. This may prove especially relevant in cancer therapy since the assay could be applied to drug screening in biopsied tumour cells.

## Conclusion

In conclusion, we report a novel cellular screening technique for assessing intracellular drug-target engagement. TAPS is a dual parameter technique which is multiplexed with respect to compound and, in a single assay method, enables identification of compounds which are cell permeable, have low cytotoxicity and demonstrate specific affinity for the target protein in a physiologically relevant environment. We demonstrated the potential for the TAPS assay by successful screening of the poorly soluble and challenging protein human, KMO. With target validation and target engagement representing two key limiting factors within the revived importance of phenotypic and high-content screening, we present this solution, which uses off-the-shelf equipment accessible to many scientists in the field. With equally high value, this straightforward workflow will allow direct screening of new targets by affinity selection that until now have only been accessible by indirect detection. We regard important potential targets to include intercompartmental membrane proteins including nuclear envelope transmembrane proteins known to be involved in many cancers. Drug discovery processes are often hindered by issues encountered during preparation of difficult target proteins. Screening of target proteins in a physiologically relevant environment using this method may present a solution, as demonstrated by successful screening of the poorly soluble and challenging protein human KMO.

## Acknowledgments

We thank Shonna Johnston and Will Ramsay at the QMRI Flow Cytometry Facility for technical assistance. We are grateful to all supporters and funders.

This work was supported by and MRC studentship to KW. DJM held a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship during this work and now gratefully acknowledges the support of the UK Medical Research Council through a Senior Clinical Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Conflicting interests

The authors have declared that no conflicting interests exist.

## ORCID iDs

Damian J Mole  <https://orcid.org/0000-0001-6884-7302>

## References

- [1] Durham T B and Blanco M J 2015 Target engagement in lead generation *Bioorg. Med. Chem. Lett.* **15** 998–1008
- [2] Kenakin T, Bylund D B, Toews M L, Mullane K, Winquist R J and Williams M 2014 Replicated, reliable and relevant-target engagement and pharmacological experimentation in the 21st century *Biochem. Pharmacol.* **87** 64–77
- [3] Schurmann M, Janning P, Ziegler S and Waldmann H 2016 Small molecule target engagement in cells *Cell Chem. Biol.* **23** 435–41
- [4] Vinegoni C, Dubach J M, Feruglio P F and Weissleder R 2016 Two-photon fluorescence anisotropy microscopy for imaging and direct measurement of intracellular drug target engagement *IEEE J. Sel. Top. Quantum Electron.* **22** 6801607
- [5] Dubach J M, Kim E, Yang K, Cuccarese M, Giedt R J, Meimetis L G, Vinegoni C and Weissleder R 2017 Quantitating drug-target engagement in single cells *in vitro* and *in vivo* *Nat. Chem. Biol.* **13** 168–73
- [6] D'Allessandro P L et al 2016 Biorthogonal probes for the study of MDM2-p53 inhibitors in cells and development of high-content screening assays for drug discovery *Angew. Chem., Int. Ed.* **55** 16026–30
- [7] Rutkowska A, Thomson D W, Vappiana J, Werner T, Mueller K M, Dittus L, Krause J, Muelbaier M, Bergamini G and Bantscheff M 2016 A modular probe strategy for drug localization, target identification and target occupancy measurement on single cell level *ACS Chem. Biol.* **11** 2541–50
- [8] Simon G M, Niphakis M J and Cravatt B F 2013 Determining target engagement in living systems *Nat. Chem. Biol.* **9** 200–5
- [9] Molina D M, Jafari R, Ignatushchenko M, Seki T, Larsson E A, Dan C, Sreekumar L, Cao Y and Nordlund P 2013 Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay *Science* **341** 84–91
- [10] Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P and Martinez Molina D 2014 The cellular thermal shift assay for evaluating drug target interactions in cells *Nat. Protocols* **9** 2100–22
- [11] Martinez Molina D and Nordlund P 2015 The cellular thermal shift assay: a novel biophysical assay for *in situ* drug target engagement and mechanistic biomarker studies *Annu. Rev. Pharmacol. Toxicol.* **56** 141–61
- [12] Giorgini F, Guidetti P, Nguyen Q V, Bennett S C and Muchowski P J 2005 A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington's disease *Nat. Genet.* **37** 526–31
- [13] Mole D J et al 2016 Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis *Nat. Med.* **22** 202–9
- [14] Okamoto H, Yamamoto S, Nozaki M and Hayaishi O 1967 On the submitochondrial localization of L-kynurenine-3-hydroxylase *Biochem. Biophys. Res. Commun.* **26** 309–14
- [15] Uemura T and Hirai K 1998 L-kynurenine 3-monooxygenase from mitochondrial outer membrane of pig liver: purification, some properties, and monoclonal antibodies directed to the enzyme *J. Biochem.* **123** 253–62
- [16] Wilson K, Mole D J, Binnie M, Homer N Z, Zheng X, Yard B A, Iredale J P, Auer M and Webster S P 2014 Bacterial expression of human kynurenine 3-monooxygenase: solubility, activity, purification *Protein Expression Purif.* **95** 96–103
- [17] Wilson K, Mole D J, Homer N Z M, Iredale J P, Auer M and Webster S P 2015 A magnetic bead-based ligand binding assay to facilitate human kynurenine 3-monooxygenase drug discovery *J. Biomol. Screening* **20** 292–8
- [18] Pellicciari R et al 1994 Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase *J. Med. Chem.* **37** 647–55
- [19] Rover S et al 1997 Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase *J. Med. Chem.* **40** 4378–85
- [20] Alberati-Giani D, Cesura A M, Broger C, Warren W D, Rover S and Malherbe P 1997 Cloning and functional expression of human kynurenine 3-monooxygenase *FEBS Lett.* **410** 407–12
- [21] Strack R L, Hein B, Bhattacharyya D, Hell S W, Keenan R J and Glick B S 2009 A rapidly maturing far-red derivative of DsRed-Express2 for whole-cell labeling *Biochemistry* **48** 8279–81